Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Iwakiri K, et al. Among authors: ihara e. J Gastroenterol. 2022 Apr;57(4):267-285. doi: 10.1007/s00535-022-01861-z. Epub 2022 Feb 28. J Gastroenterol. 2022. PMID: 35226174 Free PMC article. Review.
Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
Nakamura K, Akiho H, Ochiai T, Motomura Y, Higuchi N, Okamoto R, Matsui N, Yasuda D, Akahoshi K, Kabemura T, Ihara E, Harada N, Ito T, Takayanagi R. Nakamura K, et al. Among authors: ihara e. Hepatogastroenterology. 2010 May-Jun;57(99-100):497-500. Hepatogastroenterology. 2010. PMID: 20698216 Clinical Trial.
Evaluating the efficacy and safety of acotiamide in patients with esophagogastric junction outflow obstruction: study protocol for an investigator-initiated, multi-center, randomized, double-blind, placebo-controlled phase II trial.
Esaki M, Ihara E, Manabe N, Kawami N, Iwakiri K, Akiyama J, Kuribayashi S, Uraoka T, Ogino H, Chinen T, Misumi A, Watanabe H, Suzuki M, Kishimoto J, Ogawa Y. Esaki M, et al. Among authors: ihara e. Trials. 2023 Jul 18;24(1):459. doi: 10.1186/s13063-023-07468-w. Trials. 2023. PMID: 37464279 Free PMC article.
Hepatopancreatobiliary manifestations of inflammatory bowel disease.
Nakamura K, Ito T, Kotoh K, Ihara E, Ogino H, Iwasa T, Tanaka Y, Iboshi Y, Takayanagi R. Nakamura K, et al. Among authors: ihara e. Clin J Gastroenterol. 2012 Feb;5(1):1-8. doi: 10.1007/s12328-011-0282-1. Epub 2012 Jan 6. Clin J Gastroenterol. 2012. PMID: 26181867
Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified.
Okuno H, Ogino H, Ihara E, Nishioka K, Tanaka Y, Chinen T, Kohjima M, Oono T, Tanaka M, Goya T, Fujimori N, Iboshi Y, Gotoda T, Ogawa Y. Okuno H, et al. Among authors: ihara e. BMC Gastroenterol. 2021 Feb 16;21(1):73. doi: 10.1186/s12876-021-01656-1. BMC Gastroenterol. 2021. PMID: 33593285 Free PMC article.
189 results